Illumina Inc. (NASDAQ: ILMN) announced a new molecular residual disease research solution based on whole-genome sequencing technology. The distributed kit enables laboratories to conduct MRD detection for clinical research applications.

The solution supports tumor fingerprinting through solid tumor samples and MRD detection using blood samples, compatible with NovaSeq Systems. The workflow can be completed in five days and is optimized for analytical sensitivity as low as 10 parts per million, according to the company's statement.

The product uses Illumina's DRAGEN MRD analysis to connect tumor fingerprints to circulating tumor DNA. The company states the solution has been optimized across thousands of samples and demonstrates 99.5% analytical specificity for distinguishing tumor signals from background noise.

Mayo Clinic evaluated the workflow on a sample cohort and found high concordance among previously characterized paired samples. The results correlated with clinical and imaging results over time, according to the press release.

"We are looking forward to participating in early access and evidence generation for a tumor-informed, non-bespoke whole-genome sequencing approach to MRD," said Gang Zheng, professor of Laboratory Medicine and Pathology at Mayo Clinic.

The solution is currently available for early access to select partners and will launch for global customers next year. Illumina and Bristol Myers Squibb will present related research at the American Society of Clinical Oncology Annual Meeting.

The company is developing a complementary research workflow that will deliver ultra-sensitive MRD detection in the single-digit parts per million range using duplex reads, built on NovaSeq X advancements including 35B output and Q70 quality scores.